Pfizer projects mRNA vaccine sales will hover around $15B by 2030
Pfizer’s mRNA vaccines have been a high point for the company during the pandemic, and even with dwindling demand and government resources, the pharma is predicting $10 billion to $15 billion in annual revenue by 2030 for its mRNA vaccine portfolio (including Comirnaty, flu, the combo of Covid-flu, and shingles).
While highlighting major 2022 vaccine readouts for its pentavalent meningococcal vaccine candidate, its RSV vaccine candidate, Prevnar 20 (which Pfizer is hoping to co-administer with its seasonal flu vaccine), and more Comirnaty data, CFO Dave Denton projected a 2023 core revenue growth of 7% to 9%, from $43.9 billion in 2022 to $46.6 billion in 2023, with a full pipeline of vaccines for flu, Covid and flu, and shingles.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.